AQP4 and myeloid sarcoma: All patients were randomly assigned to the development set (composed of training and validation sets), including 231 patients (53 with MS, 129 with AQP4+ NMOSD, and 49 with MOGAD) and the testing set, including 59 patients (14 with MS, 33 with AQP4+ NMOSD, and 12 with MOGAD) at a ratio of 4:1.